Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth’s One-Two Allergy Punch: Advil Allergy Sinus To Join Alavert

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare received FDA approval for its Advil Allergy Sinus on Dec. 19, the same day it received the agency go-ahead to market its non-sedating antihistamine Alavert

You may also be interested in...



Claritin, Alavert, Advil Allergy Sinus Head Major OTC Approvals In 2002

Antihistamines accounted for the most prominent OTC approvals in 2002, with Schering-Plough Healthcare Products' Claritin franchise and Wyeth Consumer Healthcare's Alavert and Advil Allergy Sinus all receiving the FDA go-ahead during the year

Claritin, Alavert, Advil Allergy Sinus Head Major OTC Approvals In 2002

Antihistamines accounted for the most prominent OTC approvals in 2002, with Schering-Plough Healthcare Products' Claritin franchise and Wyeth Consumer Healthcare's Alavert and Advil Allergy Sinus all receiving the FDA go-ahead during the year

Claritin, Alavert, Advil Allergy Sinus Head Major OTC Approvals In 2002

Antihistamines accounted for the most prominent OTC approvals in 2002, with Schering-Plough Healthcare Products' Claritin franchise and Wyeth Consumer Healthcare's Alavert and Advil Allergy Sinus all receiving the FDA go-ahead during the year

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel